Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche Diagnostics tests described as milestone for female health

Roche Diagnostics tests described as milestone for female health

7th January 2009

Roche Diagnostics’ tests for preeclampsia have been described as an “important milestone” for female health.

The company has launched its placenta growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFly-1) immunoassays for use with the Elecsys/cobas e electrochemiluminescence systems, following CE approval, according to a statement reported on the Insciences website.

Dirk Ehlers is head of Roche Professional Diagostics and said the development is a key marker for monitoring women’s health during pregnancy.

“We are proud to be the first to provide such innovative technology to clinicians and laboratories,” he explained.

According to the company, sFly-1 and PlGF have been discovered as major players in the development of preeclampsia, so a combined ratio of these can enable physicians to differentiate normal pregnancies from those with the condition.

NHS statistics show that about one in 14 women suffer from mild preeclampsia, although not all of these require treatment. Approximately one in 100 will then develop eclampsia, which is more serious.

Each year around seven to ten females die from eclampsia as well as up to 1,000 infants.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.